NEUROG1 and colorectal carcinoma: <h4>Background</h4>To assess the status of NEUROG1 methylation in the advanced adenoma and colorectal cancer.<h4>Methods</h4>The NEUROG1 methylation in tissue and stool samples from patients with colorectal cancer (CRC), advanced adenoma (AA), and non-advanced adenoma (NAA) were evaluated using methylation-specific quantitative polymerase chain reaction (PCR).<h4>Results</h4>In tissue samples, the NEUROG1 methylation detection rates were 36% for CRC, 24% for NAA, and 88% for AA.